Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer
Phase 4
- Conditions
- Advanced or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000007246
- Lead Sponsor
- Kyushu Study group of Clinical Cancer
- Brief Summary
ASCO-GI 2017 Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study. Akitaka Makiyama, Mototsugu Shimokawa, Tomomi Kashiwada, Ikuo Takahashi, Yasunori Emi, Tetsuya Kusumoto, Kazuharu Yamamoto, Hiroshi Ishikawa, Yuji Negoro, Eiji Oki, Hiroshi Saeki, Yoshihiro Kakeji, Hideo Baba,Yoshihiko Maehara, Kyushu Study Group of Clinical Cancer (KSCC)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Other than inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety (rate and grade of adverse event) Rate and grade of Infusion reaction and treatment Rate and grade of cardiac events, and correlation with treatment and outcome Treatment line Treatment regimen Response Rate Progression Free Survival Time to Failure of Strategy Time to Treatment Failure Overall Survival
- Secondary Outcome Measures
Name Time Method